Emerging therapies for inv(16) AML

The core binding factor composed of CBFβ and RUNX subunits plays a critical role in most hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion oncogene CBFβ-SMMHC expressed in AML with the chromosome inversion inv(16)(p13q22) acts as a driver oncogene in hematopoietic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2021-05, Vol.137 (19), p.2579-2584
Hauptverfasser:	Surapally, Sridevi, Tenen, Daniel G., Pulikkan, John A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cell Transformation, Neoplastic - genetics Chromosome Inversion Chromosomes, Human, Pair 16 - genetics Chromosomes, Human, Pair 16 - ultrastructure Combined Modality Therapy Core Binding Factor Alpha 2 Subunit - deficiency Core Binding Factor Alpha 2 Subunit - metabolism Core Binding Factor beta Subunit - genetics Core Binding Factor beta Subunit - physiology Forecasting Gemtuzumab - therapeutic use Gene Expression Regulation, Leukemic Gene Knock-In Techniques Hematopoiesis - drug effects Hematopoiesis - genetics Humans Immunotherapy - methods Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Mice Molecular Targeted Therapy Myosin Heavy Chains - genetics Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Neoplastic Stem Cells - pathology Oncogene Proteins, Fusion - antagonists & inhibitors Oncogene Proteins, Fusion - genetics Oncogene Proteins, Fusion - physiology Spotlight T-Lymphocytes - immunology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!